Actinium Pharma Presents ATNM-400 Clinical Data in Prostate Cancer

Actinium Pharmaceuticals is set to present first-in-human clinical data for its ATNM-400 drug candidate at the EANM 2026 conference. The presentation will focus on Phase 1 trial results in patients with metastatic castration-resistant prostate cancer.

The company stated that ATNM-400 represents a differentiated approach in its treatment strategy. Further details on the drug's performance in this patient group are expected during the conference presentation.

In addition to the prostate cancer data, Actinium Pharmaceuticals will also share preclinical findings for ATNM-400. These studies examined the drug's potential in non-small cell lung cancer, specifically in cases driven by KRAS and ALK mutations. This research supports the drug's potential for broader application across various tumor types.

The EANM 2026 conference provides a platform for the company to share early-stage clinical and preclinical development updates with the medical and scientific community.